SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

COH Cochlear Limited

Healthcare · Medical Devices · website · 5,400 employees
$125.39
52wk 88.74 – 296.50
Overall
39.4
Value
26.4
Growth
19.9
Health
94.9
Quality
56.7
Momentum
7.7
Dividend
15.0
Price
About Cochlear Limited

Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers cochlear implant systems; replacement sound processors, accessories, and other services; bone conduction systems and replacement sound processors; and recipient support tools. The company also provides Cochlear connected care solutions, such as Cochlear Nucleus SmartNav System; Cochlear Custom Sound Pro Fitting Software; Cochlear Remote Assist; Cochlear Remote Check; and Cochlear Link. It offers its products and services under the Cochlear, Nucleus, Nexa, Osia, and Cochlear Baha brands. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.

Price analytics

Returns

1 day -3.8%
1 week -11.9%
1 month -11.1%
3 months -1.3%
6 months -29.2%
1 year -56.0%
3 years -50.9%

Risk

Volatility (1y ann.) 54.3%
Beta vs ASX 200 1.27
Sharpe (1y) -1.25
VaR 95% (1-day) -3.5%
Max drawdown (1y) -69.6%
Off 1-year high -57.7%

Technicals

RSI(14) 35
vs 50DMA -6.2%
vs 200DMA -21.3%
Trend Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 26.4
Trailing P/E
0
Forward P/E
49
PEG ratio
0
EV / EBITDA
14
Price / Book
46
Price / Sales
71
Growth 19.9
Revenue growth (1y)
29
Revenue CAGR (3y)
46
EPS growth (1y)
0
EPS CAGR (3y)
0
Financial Health 94.9
Net debt / EBITDA
98
Interest coverage (EBIT/interest)
100
Current ratio
80
Debt / Equity
100
Quality (Profitability & Cash Flow) 56.7
Return on equity
40
Return on assets
97
Operating margin
57
Net margin
42
Cash conversion (OCF / net income)
—
Dividend / Income 15.0
Dividend yield (%)
33
Payout ratio
0
FCF dividend cover
11
Momentum 7.7
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
19
Position in 52-week range
18

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$8.20B
P/E (trailing)
55.48
P/E (forward)
21.88
EPS (trailing)
2.26
Dividend yield
2.1%
Payout ratio
190.9%
Beta
0.27
EV / EBITDA
17.14
Price / Book
4.71
ROE
8.0%
Operating margin
14.3%
Net margin
6.3%
Total cash
$187.70M
Total debt
$212.70M
Current ratio
2.15
Debt / Equity
0.12
Free cash flow
$313.59M
Avg volume
557,584
Latest annual results (FY ending 30 Jun 2026)
  • Revenue$2.35B
  • Gross profit$1.66B
  • Operating income$209.20M
  • Net income$147.30M
  • Diluted EPS2.25
  • Free cash flow$277.30M
  • Net debt$25.00M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
ANN $6.27B 21.3 71.5